AU728420B2 - New use for 1,3-propanediol derivatives - Google Patents

New use for 1,3-propanediol derivatives Download PDF

Info

Publication number
AU728420B2
AU728420B2 AU54831/98A AU5483198A AU728420B2 AU 728420 B2 AU728420 B2 AU 728420B2 AU 54831/98 A AU54831/98 A AU 54831/98A AU 5483198 A AU5483198 A AU 5483198A AU 728420 B2 AU728420 B2 AU 728420B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
formula
compound
acceptable salt
recipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU54831/98A
Other languages
English (en)
Other versions
AU5483198A (en
Inventor
Sylvain Cottens
Robert Paul Hof
Roland Wenger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU5483198A publication Critical patent/AU5483198A/en
Application granted granted Critical
Publication of AU728420B2 publication Critical patent/AU728420B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Light Receiving Elements (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polyurethanes Or Polyureas (AREA)
  • Peptides Or Proteins (AREA)
AU54831/98A 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives Ceased AU728420B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9624038 1996-11-19
GBGB9624038.7A GB9624038D0 (en) 1996-11-19 1996-11-19 Organic compounds
PCT/EP1997/006408 WO1998022100A2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Publications (2)

Publication Number Publication Date
AU5483198A AU5483198A (en) 1998-06-10
AU728420B2 true AU728420B2 (en) 2001-01-11

Family

ID=10803173

Family Applications (1)

Application Number Title Priority Date Filing Date
AU54831/98A Ceased AU728420B2 (en) 1996-11-19 1997-11-17 New use for 1,3-propanediol derivatives

Country Status (24)

Country Link
US (3) US6274629B1 (enExample)
EP (2) EP1312359B1 (enExample)
JP (2) JP4004070B2 (enExample)
CN (2) CN1146411C (enExample)
AT (2) ATE275947T1 (enExample)
AU (1) AU728420B2 (enExample)
BR (1) BR9713105A (enExample)
CA (1) CA2270952C (enExample)
CZ (1) CZ174999A3 (enExample)
DE (2) DE69730727T2 (enExample)
DK (1) DK1312359T3 (enExample)
ES (2) ES2289041T3 (enExample)
GB (1) GB9624038D0 (enExample)
HU (1) HUP0000343A3 (enExample)
ID (1) ID21568A (enExample)
IL (1) IL129824A (enExample)
NO (1) NO992259L (enExample)
NZ (1) NZ335629A (enExample)
PL (1) PL190348B1 (enExample)
PT (2) PT1312359E (enExample)
RU (1) RU2217136C2 (enExample)
SI (1) SI1312359T1 (enExample)
SK (1) SK284806B6 (enExample)
WO (1) WO1998022100A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1457478B1 (en) 1998-11-11 2017-07-19 Novartis AG Production of 2-amino-2-[2-(4-alkyl-phenyl)ethyl]propane-1,3-diols
CN1411373A (zh) * 1999-12-16 2003-04-16 特瓦制药工业有限公司 制备来氟米特的新方法和新晶形的来氟米特
AU8533101A (en) 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
CA2435739A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
RU2290196C2 (ru) * 2001-04-20 2006-12-27 Дебиофарм С.А. Модифицированный циклоспорин, который можно использовать в качестве пролекарства, и его применение
PL364359A1 (en) * 2001-06-08 2004-12-13 Novartis Ag Treatment or prophylaxis of insulin-producing cell graft rejection
GB0117921D0 (en) * 2001-07-23 2001-09-12 Novartis Ag Organic compounds
US7780993B2 (en) * 2001-09-07 2010-08-24 Yeda Research And Development Co. Ltd. Therapeutic transplantation using developing, human or porcine, renal or hepatic, grafts
US20040136972A1 (en) * 2001-09-07 2004-07-15 Yeda Research And Development Co. Ltd. Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
GB0125443D0 (en) 2001-10-23 2001-12-12 Novartis Ag Organic Compounds
DE60328161D1 (de) 2002-01-11 2009-08-13 Daiichi Sankyo Co Ltd Aminoalkoholderivat oder phosphonsäurederivat und diese enthaltende medizinische zusammensetzung
GB0217777D0 (en) * 2002-07-31 2002-09-11 Novartis Ag Organic compounds
IL165425A0 (en) * 2004-11-28 2006-01-15 Yeda Res & Dev Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues
NZ592339A (en) 2003-04-08 2012-09-28 Novartis Ag Solid pharmaceutical compositions of S1P receptor agonist with sugar alcohol
US7524887B2 (en) 2003-06-06 2009-04-28 Sanofi-Aventis Deutschland Gmbh 2-amino-1,3-propanediol compounds for the treatment of acute pain
EP1484057A1 (en) * 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
CA2778126A1 (en) * 2003-06-24 2005-01-13 University Of Connecticut Methods of inhibiting vascular permeability and apoptosis
US7074659B2 (en) * 2003-11-13 2006-07-11 Volterra Semiconductor Corporation Method of fabricating a lateral double-diffused MOSFET (LDMOS) transistor
CN1921847B (zh) 2004-02-24 2010-06-16 三共株式会社 氨基醇化合物
JP5214966B2 (ja) * 2004-07-30 2013-06-19 ノバルティス アーゲー ２−アミノ−１，３−プロパンジオール化合物およびその類似体の製剤
BRPI0619894B8 (pt) 2005-12-15 2021-05-25 Mitsubishi Tanabe Pharma Corp composto de amina e composição farmacêutica
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
RU2496486C1 (ru) 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
JP6484567B2 (ja) * 2013-03-05 2019-03-13 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ ２−アミノ−１，３−プロパンジオール化合物およびその塩の製造のための方法
WO2017046345A1 (en) 2015-09-18 2017-03-23 Sanovel Ilac Sanayi Ve Ticaret A.S. Fingolimod capsule composition
JP2024521882A (ja) * 2021-05-31 2024-06-04 上海雲晟研新生物科技有限公司 フィンゴリモド薬用塩、製造方法、それを含む医薬組成物及び使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406A1 (en) * 1992-10-21 1994-12-07 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0812588A1 (en) * 1995-12-28 1997-12-17 Yoshitomi Pharmaceutical Industries, Ltd. External preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904679A (en) * 1972-05-23 1975-09-09 Upjohn Co 15-Methyl and 15-ethyl prostaglandin F{HD 2{331 {0 {B analogs
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
BR9206313A (pt) * 1991-07-25 1995-04-11 Idec Pharma Corp Anticorpos recombinantes para terapia humana.
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
CN1178653C (zh) * 1997-02-27 2004-12-08 三菱制药株式会社 药物组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0627406A1 (en) * 1992-10-21 1994-12-07 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0812588A1 (en) * 1995-12-28 1997-12-17 Yoshitomi Pharmaceutical Industries, Ltd. External preparation

Also Published As

Publication number Publication date
HUP0000343A3 (en) 2001-06-28
EP0941082B1 (en) 2004-09-15
HUP0000343A2 (hu) 2000-12-28
EP1312359B1 (en) 2007-08-15
DK1312359T3 (da) 2007-10-08
US20010056124A1 (en) 2001-12-27
DE69738033D1 (de) 2007-09-27
BR9713105A (pt) 2000-04-11
JP2004256554A (ja) 2004-09-16
CN1237906A (zh) 1999-12-08
IL129824A (en) 2003-07-31
US6486209B2 (en) 2002-11-26
DE69738033T2 (de) 2008-04-30
SK284806B6 (sk) 2005-11-03
CN1146411C (zh) 2004-04-21
SI1312359T1 (sl) 2008-08-31
WO1998022100A3 (en) 1998-06-25
US20030069315A1 (en) 2003-04-10
EP1312359A2 (en) 2003-05-21
HK1022639A1 (en) 2000-08-18
SK65999A3 (en) 1999-12-10
DE69730727D1 (de) 2004-10-21
EP0941082A2 (en) 1999-09-15
ES2227726T3 (es) 2005-04-01
WO1998022100A2 (en) 1998-05-28
CN1515253A (zh) 2004-07-28
JP2001503780A (ja) 2001-03-21
EP1312359A3 (en) 2004-01-02
CA2270952A1 (en) 1998-05-28
PL333463A1 (en) 1999-12-20
AU5483198A (en) 1998-06-10
PL190348B1 (pl) 2005-11-30
GB9624038D0 (en) 1997-01-08
NO992259D0 (no) 1999-05-10
RU2217136C2 (ru) 2003-11-27
NZ335629A (en) 2001-09-28
PT1312359E (pt) 2007-11-09
CA2270952C (en) 2007-09-18
CN1293876C (zh) 2007-01-10
IL129824A0 (en) 2000-02-29
ES2289041T3 (es) 2008-02-01
JP4004070B2 (ja) 2007-11-07
PT941082E (pt) 2004-12-31
ATE369846T1 (de) 2007-09-15
ATE275947T1 (de) 2004-10-15
CZ174999A3 (cs) 1999-08-11
DE69730727T2 (de) 2005-09-22
ID21568A (id) 1999-06-24
NO992259L (no) 1999-05-10
US6274629B1 (en) 2001-08-14

Similar Documents

Publication Publication Date Title
AU728420B2 (en) New use for 1,3-propanediol derivatives
AU716514B2 (en) Use of rapamycin derivatives in vasculopathies and xenotransplantation
US20080015261A1 (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
HK1057469A (en) Use for 1,3-propanediol compounds
HK1022639B (en) New use for 1,3-propanediol derivatives
HK1060855B (en) Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)